Dopamine agonists: structure-activity relationships.
D000818:Animals; D001060:Aporphines / Q000378:metabolism / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D004876:Ergot Alkaloids / Q000494:pharmacology; D006801:Humans; D007189:Indans / Q000494:pharmacology; D007546:Isoquinolines / Q000494:pharmacology; D051379:Mice; D008968:Molecular Conformation; D010627:Phenethylamines / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*; D013268:Stimulation, Chemical; D013329:Structure-Activity Relationship; D013764:Tetrahydronaphthalenes / Q000494:pharmacology
D001060:Aporphines; D001381:Azepines; D004876:Ergot Alkaloids; D007189:Indans; D007546:Isoquinolines; D010627:Phenethylamines; D011804:Quinolines; D011954:Receptors, Dopamine; D013764:Tetrahydronaphthalenes; D004298:Dopamine